fashion -WSS

fashion

author：hotspot 2025-10-02 23:48:25 - browse：514

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Did the public have the right to know Arthur Ashe had AIDS?

focus

hotspot

WSS

New case study details death in closely watched Alzhiemer's trial

Van's Gluten Free Original Waffles recalled for possible wheat allergen

RaDonda Vaught case: a double standard for nurses, physicians

New case study details death in closely watched Alzhiemer's trial

Food as medicine: Medically tailored meals may get standardized

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

hotspot

fashion

focus

Continuity nursing helped my family in our darkest PICU moments

Connecting traumatic brain injury and domestic violence

Trump demands the U.S. pay no more for drugs than other countries … again

Pfizer's Covid pill remains 89% effective in final analysis, company says

Wildfire smoke exposes gaps in outdoor worker protections

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Bright Health sells Medicare Advantage business to Molina

Option Care buys Amedisys in $3.6 billion home care deal

After affirmative action ruling, medical educators look to 'holistic review'

Did the public have the right to know Arthur Ashe had AIDS?

leisure time

Steward Health Care has deal to sell doctor network to UnitedHealth

A new study asks: Are we harming blood donors by taking blood?

Steward Health Care has deal to sell doctor network to UnitedHealth

Merck drug for rare lung condition set for approval in U.S.

Van's Gluten Free Original Waffles recalled for possible wheat allergen

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

focus

hotspot

focus

hotspot